Grace Halsey

Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.

A therapeutic strategy that reduces ACTH-driven androgen excess through a glucocorticoid-independent pathway could significantly improve treatment and patient QoL.

The increase in the adult population with and at risk for dementia portends future burden among groups and communities with the fewest resources to cope.

Obstructive sleep apnea during pregnancy increases risk for gestational hypertension and preeclampsia; CPAP therapy may lower risk significantly.

In secondary CVD prevention, low/moderate-dose statins plus ezetimibe were superior to high-dose statin for reducing biomarkers, myalgias but did not reduce MACE.

Simple criteria for lung cancer screening identified more people who would highly benefit, including more from racial/ethnic minority groups.

Results of the 3-year SURMOUNT-1 study reflect the longest trial to date of tirzepatide in adults with overweight/obesity and risk for developing T2D.

Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.

More than 6 in 10 adults treated with the investigational CRF1 antagonist crinecerfont reached a physiologic glucocorticoid dose with androstenedione control maintained.

Dr Richard Auchus says the ideal treatment for congenital adrenal hyperplasia is a long way off but describes a "block and replace" strategy that holds great promise.

Investigators found as much as a 2-fold difference in being diagnosed with dementia across the US, even after controlling for common individual risk factors.

Crinecerfont, a CRF1 antagonist, could help reduce glucocorticoid doses for individuals with CAH and improve physical and emotional quality of life, says leading researcher.

The influenza/COVID-19 combination did not prove noninferior to the comparator flu vaccine against influenza B, the companies reported.

Patients were the driving force behind the development of the needle-free epinephrine nasal spray, Casale says; he answers more questions with primary care in mind.

If approved the selective NaV1.8 pain signal inhibitor would reflect the first new class of pain management medication in more than 20 years.

The approval of neffy (epinephrine nasal spray) could help individuals and caregivers act sooner and feel safer treating a type 1 allergic reaction.

White coat and masked hypertension can be elusive and dangerous. Click through a topline look at recommendations from the 2017 ACC/AHA hypertension guidelines.

Richard J Auchus, MD, PhD, a preeminent steroid biologist, provides a concise and thorough primer on CAH and the challenges in managing the disorder safely and effectively.

Of the 25 routine lab tests studied, none proved clinically useful for diagnosing COVID-19, even among participants with a high long COVID symptom burden.

No health system across the 28 analyzed in this study demonstrated appropriate SGLT2i prescribing for more than 25% of eligible individuals.

Incretin analogues, an oral glucose formulation that targets endogenous nutrient-sensing pathways and a cannabinoid receptor 1 antagonist are in the new mix.

In a head-to-head real world study, tirzepatide compared with semaglutide resulted in 42%, 20%, and 46% reduced risks for all-cause mortality and major adverse CV and renal events, respectively.

RSVPreF induced strong neutralizing responses in immunocompromised adults aged 18 years and older in substudy B of the ongoing phase 3 MONET clinical trial.

Wyoming, Louisiana, and Oklahoma have the lowest percentage of population with shots in arms based on state population. Is your state among the other 7?

neffy (epinephrine nasal spray) is the first alternative to epinephrine administered by autoinjector or syringe and is comparable in efficacy to the gold standard.

COVID-19 as a cause of death fell from the #4 spot in 2022 to #10 in 2023, which may account for some of the overall decline in the US mortality rate, suggest CDC experts.

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

New study findings suggest that in older adults stable HbA1c within individualized target ranges over time may help reduce risk of Alzheimer disease and other dementias.

Clinical guideline recommendations for optimal timing to gauge glucocorticoid treatment effects in congenital adrenal hyperplasia require individualization. Here's why.

In young adults with congenital adrenal hyperplasia of age to transition to adult care, 25% to 50% are not successful. Here are thoughts on problems and solutions.